BYSI

BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.

Wall Street analysts forecast BYSI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BYSI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Beyondspring Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Beyondspring Inc. EPS for the last quarter amounts to -0.04 USD, decreased -20.00 % YoY.

Beyondspring Inc (BYSI) has 40 emplpoyees as of December 15 2025.

Today BYSI has the market capitalization of 86.77M USD.